Aim: Metastatic colorectal cancer (mCRC) is associated with poor prognosis, and biomarkers are required for predicting survival and chemotherapy response. This study aimed to evaluate the significance of changes in systemic inflammatory markers and carcinoembryonic antigen (CEA) levels in predicting mCRC prognosis and chemotherapy response.
INTRODUCTION
Colorectal cancer (CRC) accounts for > 9% of all cancer cases and is the fourth most common cause of cancer-related death. 1 However, overall survival (OS) remains poor despite improvements in systemic chemotherapy. 2 Moreover, chemotherapy is completely ineffective in some patients, who experience dismal survival outcomes. Thus, there is an urgent need for new biomarkers that can predict chemotherapy response and survival.
Systemic inflammatory markers have recently been reported to be correlated with survival among patients with various types of cancers, including CRC. [3] [4] [5] Furthermore, inflammation is a critical component of tumor progression, and the causal relationship between inflammation and cancer is widely accepted. 6 Thus, extensive research in several human cancers, including CRC, has examined the predictive value of inflammatory markers such as serum albumin and Creactive protein (CRP) levels, which are components of the modified Glasgow prognostic score (mGPS). 7 The neutrophil-to-lymphocyte ratio (NLR) is another inflammatory marker; an elevated NLR indicates the combined state of neutrophilia (which suggests the presence of systemic inflammation), relative lymphopenia and a cell-mediated immune response. 8 Moreover, an increased NLR may reflect the proliferative potential of tumor cells, and is associated with poor prognosis. 9 However, most studies have been conducted in the preoperative setting, 10, 11 and few studies have examined systemic inflammatory markers in patients with metastatic colorectal cancer (mCRC).
Carcinoembryonic antigen (CEA) is another important marker in mCRC. 12 Although elevated CEA levels may be associated with poor prognosis in mCRC, 13, 14 few studies have evaluated their ability to predict prognosis among patients with mCRC. Furthermore, CEA levels can be used to monitor patients with advanced CRC, 15 although there is no consensus regarding any relationship between changes in CEA levels and chemotherapy response. We evaluated the clinical significance in changes in systemic inflammatory markers (NLR and mGPS) and CEA levels in predicting the prognosis and chemotherapy response of patients with mCRC. In addition, we assessed the correlations between these factors to evaluate the relationship between inflammation and tumor extent.
PATIENTS AND METHODS

Study population
This study was approved by the institutional review board of Seoul St. 2014. Of these, 51 patients with confounding conditions (e.g. concomitant infection, autoimmune disease, steroid treatment and other recognizable inflammatory conditions) were excluded. We also excluded two patients with bone marrow suppression within 1 year after receiving chemotherapy for another disease. All diagnoses were confirmed via a biopsy or surgical specimen from the primary tumor. Histological types were classified as well-/moderately differentiated or poorly differentiated/mucinous adenocarcinoma/signet ring cell adenocarcinoma. Metastatic presentation was defined as metachronous or synchronous, and the primary tumor's status during chemotherapy initiation was defined as resected or not resected.
Chemotherapy protocol and tumor response
All patients received combination oxaliplatin-or irinotecan-based first-line chemotherapy with target agent (bevacizumab or cetuximab)
or not. The chemotherapy protocol included dexamethasone treatment (8 mg) 30 min before the infusion. All blood sampling procedures for complete blood count and blood chemistry testing were performed 4-24 h before the infusion. Initial imaging evaluations included abdomen and chest computed tomography 1 week before chemotherapy initiation, and patients were subsequently evaluated for chemotherapy response every 8 ± 2 weeks. However, 26 patients underwent their first response evaluation after 4-6 weeks based on the clinician's concern regarding the possibility of rapid progression.
No granulocyte colony-stimulating factor was administered during the 14 days before blood sampling and response evaluation. Radiological changes were evaluated using the Response Evaluation Criteria for Solid Tumors (RECIST) criteria. 16 
Measuring systemic inflammatory markers and CEA levels
Systemic inflammation status was assessed using NLR (high NLR: > 3; low NLR: ≤3, based on a median NLR of 2.51) and mGPS. The mGPS results were calculated using CRP and albumin levels: two points for patients with elevated CRP levels (> 1 mg/dL) and hypoalbuminemia (< 3.5 g/dL), one point for patients with elevated CRP levels and normal albumin levels and zero point for patients with normal CRP and albumin levels. A previous study 17 demonstrated that a score of 2 is more sensitive in predicting poor prognosis, compared to a score of 0-1. Therefore, we categorized patients with a score of 2 as having high mGPS, and patients with a score of 0-1 as having low mGPS. Changes in the NLR and mGPS values from baseline to the first postchemotherapy evaluation were categorized into group A (low-to-low, L to L), group B (high-to-low, H to L), group C (low-to-high, L to H) and group D (highto-high, H to H).
Serum CEA levels were measured using an electrochemiluminescent immunoassay (normal: < 5 ng/mL). The changes in CEA levels (baseline to first postchemotherapy evaluation) were defined as CEA-complete response (CEA-CR; < 5 ng/mL), CEA-partial response (CEA-PR; ≥50% decrease in CEA levels, but absolute values of ≥5 ng/mL), CEA-progressive disease (CEA-PD; ≥50% increase in CEA levels) and CEA-stable disease (CEA-SD; change in CEA levels that did not qualify for CEA-CR/-PR/-PD). These change patterns are collectively referred to as the "CEA response."
Statistical analysis
OS and progression-free survival (PFS) were calculated from the date of starting first-line palliative chemotherapy until the date of death or disease progression, respectively. Objective response was defined as CR or PR, and disease control was defined as complete response (CR), partial response (PR) or stable disease (SD). For the survival analyses, patients who were alive and without disease progression were censored from the date of last contact. Univariate analyses for OS and PFS were performed using the Kaplan-Meier method with the log-rank test. Multivariate Cox forward stepwise regression models were used to verify the predictive value of the systemic inflammatory markers and CEA levels, and were adjusted for age, sex, cancer location, histological type, metastatic presentation, number of metastatic organs, primary tumor status and first-line chemotherapy regimen. The significance of correlations between the systemic inflammatory markers, CEA levels and RECIST-based chemotherapy response was analyzed using the linear by linear association test. All analyses were performed using SPSS software (version 22; SPSS Inc., Chicago, Illinois, USA), and a two-sided P-value of < 0.05 was considered statistically significant. CEA, carcinoembryonic antigen; diff., differentiated; mGPS, modified Glasgow prognostic score; NLR, neutrophil-to-lymphocyte ratio.
TA B L E 1 Baseline characteristics (n = 503)
RESULTS
Patient characteristics
We included 503 patients (317 men, 63%; 186 women, 37%) with a median age of 62 years (range, 18-88 years) ( 
The markers' abilities to predict survival outcomes
Univariate analyses ( Supplementary Table S1 ) revealed that poor survival was significantly associated with poorly differentiated/mucinous adenocarcinoma/signet ring cell adenocarcinoma (OS, hazard ratio Table 2 ).
Univariate analyses revealed that poor survival was significantly associated with high prechemotherapy NLR (OS and PFS: P < 0.001), mGPS (OS: P < 0.001; PFS: P = 0.001) and CEA levels (OS and PFS: Figure S2) , as well as high postchemotherapy NLR, mGPS and CEA levels (all OS and PFS: P < 0.001) (Supplementary Figure S3 ). Multivariate analyses revealed that poor survival was independently associated with prechemotherapy NLR (OS: P = 0.001; PFS: P = 0.01), mGPS (OS: P = 0.003; PFS: P = 0.046) and CEA levels (OS and PFS: P < 0.001) ( Table 2) , as well as high postchemotherapy NLR (OS and PFS: P < 0.001) and CEA levels (OS and PFS: P < 0.001) (Supplementary Table S4 ).
Survival and chemotherapy response according to change patterns
Supplementary Table S5 showed the correlation between radiologic response and the change pattern of NLR, mGPS and CEA. Table 3 shows CEA, carcinoembryonic antigen; CR, complete response; DCR, disease control rate; mGPS, modified Glasgow prognostic score; NLR, neutrophil-tolymphocyte ratio; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease; NLR-A, low to low; NLR-B, high to low; NLR-C, low to high; NLR-D, high to high; mGPS-A, low to low; mGPS-B, high to low; mGPS-C, low to high; mGPS-D, high to high.
compared to the CEA-SD and CEA-PD groups (P < 0.001). A better CEA response was significantly associated with a better DCR (P < 0.001). (Table 4) .
F I G U R E 1 Kaplan-Meier curves for OS and PFS according to the change patterns of NLR (A, D), mGPS (B, E) and CEA levels (C, F). Patients in the NLR-A group (L to L) exhibited significantly longer OS (A) and PFS (D), compared to the NLR-B (H to L), NLR-C (L to H) and NLR-D (H to H) groups (OS and PFS: P < 0.001). Patients in the mGPS-A (L to L) group exhibited significantly longer OS (B) and PFS (E), compared to the mGPS-B (H to L), mGPS-C (L to H) and mGPS-D (H to H) groups (OS and PFS: P < 0.001). Patients with CEA-CR exhibited better OS (C) and PFS (F)
, compared to patients with CEA-PR, CEA-SD and CEA-PD (OS and PFS: P < 0.001). CEA, carcinoembryonic antigen; mGPS, modified Glasgow prognostic score; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival; PFS, progression-free survival CEA, carcinoembryonic antigen; CI, confidence interval; diff., differentiated; Muc., mucinous; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival; PFS, progression-free survival; Signet., signet ring cell.
TA B L E 4 Multivariate analysis of change patterns in systemic inflammatory markers and CEA levels for OS and PFS
OS PFS
HR
Correlations of NLR and mGPS with CEA levels
High NLR was significantly correlated with elevated CEA levels (prechemotherapy, P = 0.001; postchemotherapy, P = 0.004).
High mGPS was positively correlated with elevated CEA levels (prechemotherapy, P = 0.002; postchemotherapy, P = 0.001) (Supplementary Table S6 ).
DISCUSSION
The present study aimed to examine the value of changes in systemic inflammatory markers and CEA levels in predicting survival and response to first-line palliative chemotherapy in patients with mCRC. We found that poorly differentiated/mucinous/signet ring cell carcinoma, multiple metastatic organs and no primary tumor resection were associated with poorer prognosis; these results agree with the findings of previous studies. [18] [19] [20] We also found that systemic inflammatory markers and CEA levels were associated with the survival and response outcomes.
Inflammation and cancer are strongly associated, and it is clear that cellular proliferation alone does not cause cancer, which requires sustained cellular proliferation in an environment that is rich in inflammatory cells, growth factors, activated stroma and agents that promote DNA damage. 6 Systemic inflammatory markers, such as NLR and mGPS, are clinically useful markers of systemic inflammatory response, and are independent markers for poor survival among patients with various cancers (including CRC). 21, 22 However, the preoperative setting has typically been used to examine the relationship between systematic inflammation and prognosis among patients with CRC. 10, 11 Although a few studies have evaluated mCRC, 7 these studies typically evaluated systematic inflammation at the start of chemotherapy, and very few have evaluated posttreatment changes in inflammatory markers and their association with prognosis. 18 In addition, few studies have evaluated more than one inflammatory marker and tumor marker together. To the best of our knowledge, this is the first study to reveal the clinical significance of prechemotherapy values, postchemotherapy values and change patterns in NLR, mGPS and CEA levels among patients with mCRC. Our findings indicate that high prechemotherapy NLR and mGPS are associated with poor response and survival outcomes. These results are consistent with previous studies' findings that prechemotherapy inflammatory marker levels are associated with a poor prognosis. 7, 23 Interestingly, a high postchemotherapy NLR was also associated with poor outcomes, and patients who exhibited a change from low prechemotherapy NLR to high postchemotherapy NLR experienced dismal outcomes. In contrast, NLR reduction was an independent predictor of good prognosis and chemotherapy response. Therefore, the change patterns in NLR can be used to predict chemotherapy response and prognosis. Based on these results, we suggest that chemotherapy resistance is indicated by a continuously high NLR or a postchemotherapy change to high NLR, which indicates a persistent systemic inflammatory state. Moreover, NLR monitoring may identify patients who will experience a low response to chemotherapy.
Although there is no specific treatment for an ongoing systemic inflammatory response, anti-inflammatory drugs, such as aspirin, may be associated with a reduced risk of overall mortality among patients with colon cancer. 24 Therefore, anti-inflammatory agents may help improve the prognosis of patients with cancer and ongoing systematic inflammation. However, further studies are required to examine this issue.
Despite remarkable developments in the field of immunotherapy, there are currently no markers that can predict response to immunotherapies. Nevertheless, systemic inflammatory markers may be particularly relevant in the development of drugs that target immune checkpoints, such as antibodies to cytotoxic T-lymphocyteassociated protein 4, programed cell death protein 1 and programmed death-ligand 1. 25 Further studies are required to evaluate the value of systematic inflammatory markers, such as NLR, in predicting immunotherapy response.
The levels of CEA in patients with CRC are strongly associated with the preoperative tumor extent, outcomes and recurrence. 26 In the present study, we observed that high prechemotherapy CEA levels could predict chemotherapy response and prognosis. These findings are consistent with the findings of previous studies, 27 which demonstrated that baseline CEA levels are associated with prognosis. In addition, postchemotherapy CEA levels significantly predicted prognosis in the present study. When we evaluated the relationship between systemic inflammatory markers and CEA levels, we found that NLR and mGPS were significantly correlated with CEA levels. Given that serum CEA levels may reflect tumor burden and extent in patients with CRC, 28 our results indirectly indicate a strong relationship between tumor extent and systemic inflammation. This result supports the findings of previous studies, 6 which demonstrated that a tumor's abundant production of proinflammatory cytokines can lead to a level of inflammation that potentiates tumor growth. Nevertheless, further studies are required to evaluate the clinical significance of the relationship between systemic inflammation and tumor extent among patients with cancer, and to investigate appropriate treatment strategies for these patients.
The present study has several limitations. First, unlike the NLR evaluation, the postchemotherapy mGPS and its changes in pattern may not be suited for predicting survival. For example, some patients with gastrointestinal cancer exhibit malnutrition-related hypoalbuminemia, which raises the question of whether a high mGPS reflects true inflammation. In contrast, some patients receive albumin replacement, which can induce pseudo-normal albuminemia. Thus, it is possible that postchemotherapy mGPS and its changes in pattern may not be suitable for survival analyses, and further studies are required to examine this issue. Second, this study utilized a retrospective design, which is associated with well-known limitations. Especially, we could not perform an analysis about more prognostic factors such as molecular marker (RAS/B-RAS/MSI), colon sideness due to retrospective design. We think that further study about this should be needed. Third, the optimal measurement timing and cutoff levels for NLR, mGPS and
